Chronic prostatitis may refer to:

Chronic prostatitis/chronic pelvic pain syndrome (about 90-95% of cases)
Chronic bacterial prostatitis
Asymptomatic inflammatory prostatitis
Legal status
In February 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Jemperli, intended for the treatment of certain types of recurrent or advanced endometrial cancer. The applicant for this medicinal product is GSK (Ireland) Limited. Dostarlimab was approved for medical use in the European Union in April 2021. Economics
In the United States, dostarlimab is an expensive medication, costing around US$11,000 per dose.For patients with endometrial cancer it is estimated cost of dostarlimab is $104,000 in the first 6 months. This only includes the cost of accessing the medication and not the doctors fee or infusion cost or imaging. Thus those who are uninsured will most likely have trouble getting treatment with Dostarlimab. Among those who are insured, those who have Medicaid insurance are less likely to receive full care for gynecologic cancer. Those insured through private insurance still experience economical hardships while getting treatment. Uninsured patients do not tend to get screened regularly, which results in late diagnosis of the disease. References
External links
"Dostarlimab". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT02715284 for "Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET)" at ClinicalTrials.gov